Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06016738




Registration number
Help: Registration number
NCT06016738
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
17/08/2023
Date registered
Help: Date registered
30/08/2023
Date last updated
Help: Date last updated
13/08/2026

Titles & IDs
Public title
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Scientific title
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Additional trial identifiers [1] 0 0
OPERA-01
Additional trial identifiers [2] 0 0
OP-1250-301
Universal Trial Number (UTN)
Trial acronym
OPERA-01
Related trial records

Health condition
Health condition(s) studied:
Breast Cancer 0 0
Advanced Breast Cancer 0 0
Metastatic Breast Cancer 0 0
ER Positive Breast Cancer 0 0
HER2 Negative Breast Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Palazestrant
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Anastrozole
Treatment: Drugs - Letrozole
Treatment: Drugs - Exemestane

Experimental: Palazestrant (OP-1250) - Participants will receive Palazestrant

Active comparator: Standard of Care Endocrine Therapy - Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)


Treatment: Drugs: Palazestrant
Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.

Treatment: Drugs: Fulvestrant
Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle

Treatment: Drugs: Anastrozole
Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle

Treatment: Drugs: Letrozole
Participants will be treated with letrozole once daily on a 4 week (28 day) cycle

Treatment: Drugs: Exemestane
Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Dose-Selection Part: Incidence of adverse events
Timepoint [1] 0 0
From Date of Randomization up to 16 weeks
Primary outcome [2] 0 0
Dose-Selection Part: Incidence of dose reduction
Timepoint [2] 0 0
From Date of Randomization up to 16 weeks
Primary outcome [3] 0 0
Dose-Selection Part: Incidence of drug discontinuation
Timepoint [3] 0 0
From Date of Randomization up to 16 weeks
Primary outcome [4] 0 0
Trial: Progression-Free Survival (PFS)
Timepoint [4] 0 0
From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)
Secondary outcome [1] 0 0
Trial: Overall Survival (OS)
Timepoint [1] 0 0
From Date of Randomization until Death Due to Any Cause (estimated as up to 4 years)

Eligibility
Key inclusion criteria
Key inclusion criteria:

* Adult female or male participants.
* ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
* Evaluable disease (measurable disease or bone-only disease).
* Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate hematologic, hepatic, and renal functions.
* Female participants can be pre-, peri- or postmenopausal.
* Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.

Key exclusion criteria:

* Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.
* Previously received chemotherapy in the advanced/metastatic setting.
* Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.
* History of allergic reactions to study treatment.
* Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information.
* Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.
* Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/02/2028
Actual
Sample size
Target
510
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Clinical Trial Site - Gosford
Recruitment hospital [2] 0 0
Clinical Trial Site - Westmead
Recruitment hospital [3] 0 0
Clinical Trial Site - Adelaide
Recruitment hospital [4] 0 0
Clinical Trial Site - Ballarat Central
Recruitment hospital [5] 0 0
Clinical Trial Site - Clayton
Recruitment hospital [6] 0 0
Clinical Trial Site - Shepparton
Recruitment hospital [7] 0 0
Clinical Trial Site - Nedlands
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3355 - Ballarat Central
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3630 - Shepparton
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Córdoba Province
Country [26] 0 0
Argentina
State/province [26] 0 0
Jujuy Province
Country [27] 0 0
Argentina
State/province [27] 0 0
La Rioja Province
Country [28] 0 0
Argentina
State/province [28] 0 0
Río Negro Province
Country [29] 0 0
Argentina
State/province [29] 0 0
Santa Fe Province
Country [30] 0 0
Argentina
State/province [30] 0 0
Tucumán Province
Country [31] 0 0
Austria
State/province [31] 0 0
Wels
Country [32] 0 0
Austria
State/province [32] 0 0
Wiener Neustadt
Country [33] 0 0
Belgium
State/province [33] 0 0
Antwerpen
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels Capital
Country [35] 0 0
Belgium
State/province [35] 0 0
Hainaut
Country [36] 0 0
Belgium
State/province [36] 0 0
Vlaams Brabant
Country [37] 0 0
Brazil
State/province [37] 0 0
Estado de Bahia
Country [38] 0 0
Brazil
State/province [38] 0 0
Federal District
Country [39] 0 0
Brazil
State/province [39] 0 0
Maranhão
Country [40] 0 0
Brazil
State/province [40] 0 0
Minas Gerais
Country [41] 0 0
Brazil
State/province [41] 0 0
Paraná
Country [42] 0 0
Brazil
State/province [42] 0 0
Pernambuco
Country [43] 0 0
Brazil
State/province [43] 0 0
Rio Grande do Sul
Country [44] 0 0
Brazil
State/province [44] 0 0
Santa Catarina
Country [45] 0 0
Brazil
State/province [45] 0 0
São Paulo
Country [46] 0 0
Brazil
State/province [46] 0 0
Porto Alegre
Country [47] 0 0
Brazil
State/province [47] 0 0
Rio de Janeiro
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Pazardzhik
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Sofia-Grad
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Vratsa
Country [51] 0 0
Canada
State/province [51] 0 0
Alberta
Country [52] 0 0
Canada
State/province [52] 0 0
Ontario
Country [53] 0 0
Canada
State/province [53] 0 0
Quebec
Country [54] 0 0
Czechia
State/province [54] 0 0
Hradec Králové Region
Country [55] 0 0
Czechia
State/province [55] 0 0
Moravian-Silesian Region
Country [56] 0 0
Czechia
State/province [56] 0 0
Olomouc Region
Country [57] 0 0
Czechia
State/province [57] 0 0
Brno
Country [58] 0 0
Czechia
State/province [58] 0 0
Prague
Country [59] 0 0
France
State/province [59] 0 0
Ain
Country [60] 0 0
France
State/province [60] 0 0
Doubs
Country [61] 0 0
France
State/province [61] 0 0
Loire-Atlantique
Country [62] 0 0
France
State/province [62] 0 0
Oise
Country [63] 0 0
France
State/province [63] 0 0
Puy-de-Dôme
Country [64] 0 0
France
State/province [64] 0 0
Sarthe
Country [65] 0 0
France
State/province [65] 0 0
Val-de-Marne
Country [66] 0 0
France
State/province [66] 0 0
Caen
Country [67] 0 0
France
State/province [67] 0 0
Montpellier
Country [68] 0 0
France
State/province [68] 0 0
Paris
Country [69] 0 0
Germany
State/province [69] 0 0
Baden-Wurttemberg
Country [70] 0 0
Germany
State/province [70] 0 0
North Rhine-Westphalia
Country [71] 0 0
Germany
State/province [71] 0 0
Saxony
Country [72] 0 0
Germany
State/province [72] 0 0
Schleswig-Holstein
Country [73] 0 0
Hong Kong
State/province [73] 0 0
Hong Kong
Country [74] 0 0
Hungary
State/province [74] 0 0
Baranya
Country [75] 0 0
Hungary
State/province [75] 0 0
Bács-Kiskun county
Country [76] 0 0
Hungary
State/province [76] 0 0
Hajdú-Bihar
Country [77] 0 0
Italy
State/province [77] 0 0
Campania
Country [78] 0 0
Italy
State/province [78] 0 0
Emilia-Romagna
Country [79] 0 0
Italy
State/province [79] 0 0
Friuli Venezia Giulia
Country [80] 0 0
Italy
State/province [80] 0 0
Lazio
Country [81] 0 0
Italy
State/province [81] 0 0
Lombardy
Country [82] 0 0
Italy
State/province [82] 0 0
Piacenza
Country [83] 0 0
Italy
State/province [83] 0 0
Piedmont
Country [84] 0 0
Italy
State/province [84] 0 0
Pordenone
Country [85] 0 0
Italy
State/province [85] 0 0
Ancona
Country [86] 0 0
Italy
State/province [86] 0 0
Genova
Country [87] 0 0
Italy
State/province [87] 0 0
Naples
Country [88] 0 0
Italy
State/province [88] 0 0
Padova
Country [89] 0 0
Italy
State/province [89] 0 0
Pavia
Country [90] 0 0
Malaysia
State/province [90] 0 0
Kedah
Country [91] 0 0
Malaysia
State/province [91] 0 0
Kelantan
Country [92] 0 0
Malaysia
State/province [92] 0 0
Perak
Country [93] 0 0
Malaysia
State/province [93] 0 0
Pulau Pinang
Country [94] 0 0
Malaysia
State/province [94] 0 0
Putramya
Country [95] 0 0
Malaysia
State/province [95] 0 0
Sarawak
Country [96] 0 0
Malaysia
State/province [96] 0 0
Selangor
Country [97] 0 0
Malaysia
State/province [97] 0 0
WP
Country [98] 0 0
Mexico
State/province [98] 0 0
Jalisco
Country [99] 0 0
Mexico
State/province [99] 0 0
Mexico City
Country [100] 0 0
Mexico
State/province [100] 0 0
Puebla
Country [101] 0 0
Mexico
State/province [101] 0 0
San Luis Potosí
Country [102] 0 0
Mexico
State/province [102] 0 0
Monterrey
Country [103] 0 0
Mexico
State/province [103] 0 0
Oaxaca City
Country [104] 0 0
Mexico
State/province [104] 0 0
Sinaloa
Country [105] 0 0
Netherlands
State/province [105] 0 0
North Holland
Country [106] 0 0
Netherlands
State/province [106] 0 0
South Holland
Country [107] 0 0
Poland
State/province [107] 0 0
Lublin Voivodeship
Country [108] 0 0
Poland
State/province [108] 0 0
Lódzkie
Country [109] 0 0
Poland
State/province [109] 0 0
Masovian Voivodeship
Country [110] 0 0
Poland
State/province [110] 0 0
Podkarpackie Voivodeship
Country [111] 0 0
Poland
State/province [111] 0 0
Pomeranian Voivodeship
Country [112] 0 0
Poland
State/province [112] 0 0
Gdansk
Country [113] 0 0
Poland
State/province [113] 0 0
Krakow
Country [114] 0 0
Poland
State/province [114] 0 0
Poznan
Country [115] 0 0
Poland
State/province [115] 0 0
Wroclaw
Country [116] 0 0
Portugal
State/province [116] 0 0
Coimbra District
Country [117] 0 0
Portugal
State/province [117] 0 0
Lisbon District
Country [118] 0 0
Portugal
State/province [118] 0 0
Porto District
Country [119] 0 0
Puerto Rico
State/province [119] 0 0
Puerto Rico
Country [120] 0 0
Romania
State/province [120] 0 0
Bihor County
Country [121] 0 0
Romania
State/province [121] 0 0
Bra?ov County
Country [122] 0 0
Romania
State/province [122] 0 0
Bucharest
Country [123] 0 0
Romania
State/province [123] 0 0
Cluj
Country [124] 0 0
Romania
State/province [124] 0 0
Dolj
Country [125] 0 0
Romania
State/province [125] 0 0
Iasi
Country [126] 0 0
Romania
State/province [126] 0 0
Timi? County
Country [127] 0 0
Romania
State/province [127] 0 0
Ia?i
Country [128] 0 0
South Korea
State/province [128] 0 0
Gyeonggi-do
Country [129] 0 0
South Korea
State/province [129] 0 0
Busan
Country [130] 0 0
South Korea
State/province [130] 0 0
Seoul
Country [131] 0 0
South Korea
State/province [131] 0 0
Suwon
Country [132] 0 0
Spain
State/province [132] 0 0
Badajoz
Country [133] 0 0
Spain
State/province [133] 0 0
Barcelona
Country [134] 0 0
Spain
State/province [134] 0 0
Girona
Country [135] 0 0
Spain
State/province [135] 0 0
León
Country [136] 0 0
Spain
State/province [136] 0 0
Lleida
Country [137] 0 0
Spain
State/province [137] 0 0
Madrid
Country [138] 0 0
Spain
State/province [138] 0 0
Navarre
Country [139] 0 0
Spain
State/province [139] 0 0
Sevilla
Country [140] 0 0
Spain
State/province [140] 0 0
Tarragona
Country [141] 0 0
Spain
State/province [141] 0 0
Valencia
Country [142] 0 0
Spain
State/province [142] 0 0
Alicante
Country [143] 0 0
Spain
State/province [143] 0 0
Fuenlabrada
Country [144] 0 0
Spain
State/province [144] 0 0
Murcia
Country [145] 0 0
Spain
State/province [145] 0 0
Santa Cruz de Tenerife
Country [146] 0 0
Spain
State/province [146] 0 0
Santiago de Compostela
Country [147] 0 0
Taiwan
State/province [147] 0 0
Changhua
Country [148] 0 0
Taiwan
State/province [148] 0 0
Kaohsiung City
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taichung
Country [150] 0 0
Taiwan
State/province [150] 0 0
Tainan
Country [151] 0 0
Taiwan
State/province [151] 0 0
Taipei
Country [152] 0 0
Thailand
State/province [152] 0 0
Bangkok
Country [153] 0 0
Thailand
State/province [153] 0 0
Chiang Mai
Country [154] 0 0
Thailand
State/province [154] 0 0
Samut Sakhon
Country [155] 0 0
Thailand
State/province [155] 0 0
Songkhla
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Leicestershire
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Nottingham
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Somerset
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Bodelwyddan
Country [160] 0 0
United Kingdom
State/province [160] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Olema Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director, MD
Address 0 0
Olema Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Olema Pharmaceuticals, Inc.
Address 0 0
Country 0 0
Phone 0 0
415-651-7206
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06016738